NEW YORK (AP) -- Drug developer Sanofi-Aventis said Monday its irregular heart rhythm drug Multaq received regulatory approval in the European Union.

The European Commission granted approval for the drug, which clears the way for sales in all 27 European member states. The drug is already approved in the U.S.

Shares of Paris-based Sanofi-Aventis closed at $38.43 Friday.